格隆汇1月30日丨海利生物(603718.SH)公布，公司预计2025年年度实现利润总额3400万元到4000万元， 实现归属于母公司所有者的净利润1100万元到1600万元，归属于母公司所有者的扣除非经常性损益后的 净利润为-4亿元到-3.9亿元。预计2025年年度实现营业收入和扣除与主营业务无关的业务收入和不具备 商业实质的收入后的营业收入为1.9亿元到1.95亿元，低于3亿元。 本期业绩下滑的主要原因：1、2024年公司因出售 WuXi Vaccines（Cayman）Inc.（开曼药明海德有限公 司）30%非控股股权实现的投资收益超过1亿元，导致公司上年同期的非经常损益大幅增加，形成了较 高的对比基数。同时，公司全资子公司上海捷门生物技术有限公司受 IVD 行业集采、DRG（疾病诊断 相关分组）/DIP（病种分值付费）政策的影响，业绩出现下滑，存在商誉减值风险，公司将对收购捷门 生物产生的商誉进行减值测试，并基于测试结果计提相应的商誉减值准备。 2、公司控股子公司陕西瑞盛生物科技有限公司从2025 年二季度开始，受国家政策影响导致行业竞争者 增加引发的"价格战"影响显现及原相关税收优惠政策执行收紧落实 ...

Core Viewpoint - The cancellation of the VAT exemption for contraceptive drugs and devices aims to standardize tax incentives and promote tax fairness [1][2] Group 1: Tax Policy Changes - The removal of the VAT exemption means that contraceptive products will now be subject to the same VAT rates and deduction mechanisms as other ordinary goods, promoting a unified tax system and fair tax burden [1] - The adjustment reflects a response to the evolving needs of the economy and aims to support high-quality development by reassessing and regulating specific historical tax incentives [1] Group 2: Market Impact - The reintroduction of VAT on contraceptive products is expected to have a limited impact on market supply and will not significantly disrupt the industry chain or alter the basic supply-demand balance [2] - Although companies will incur a 13% VAT on sales, they will also gain the right to deduct input VAT, leading to a relatively minor increase in actual tax burden and minimal effect on final market prices [2] - A unified and standardized VAT system is anticipated to enhance fair competition in the market and ensure the quality and stability of market supply in the long term [2]

Group 1 - The new VAT law will come into effect on January 1, 2026, removing the exemption for contraceptive drugs and devices, which will now be subject to a 13% VAT rate [2] - The removal of the VAT exemption for contraceptive products aligns with China's changing population policies, which now encourage childbirth rather than limiting it [3] - The decision to impose VAT on contraceptive products is part of a broader effort to standardize tax treatment across various goods and services, reflecting the current demographic strategy of the government [2][3] Group 2 - The Ministry of Finance reported that the domestic VAT revenue reached 58.58 billion yuan in the first ten months of the year, showing a year-on-year growth of 4% [3] - The adjustment in tax policy is expected to generate additional fiscal resources that can be redirected to support pro-natalist measures, such as child-rearing subsidies and the removal of certain fees [3] - Experts suggest that outdated and unreasonable tax incentives should gradually be phased out as part of the ongoing tax reform efforts [3]

Core Viewpoint - The upcoming implementation of the VAT law on January 1, 2026, will remove the exemption for contraceptive drugs and devices, leading to a 13% VAT rate that will ultimately be borne by consumers [1][2]. Group 1: Tax Policy Changes - The VAT law will officially take effect on January 1, 2026, and will no longer include contraceptive drugs and devices in the exempt category [1]. - The removal of the exemption aligns with China's current population policy, which encourages childbirth, thus necessitating a change in tax treatment for contraceptive products [2]. Group 2: Historical Context - Contraceptive drugs and devices were exempt from VAT since the provisional regulations were first published in 1993, aimed at reducing costs associated with family planning [1]. - The shift in tax policy reflects a broader change in China's demographic strategy, moving from population control to encouraging higher birth rates [2]. Group 3: Financial Implications - The VAT is the largest tax category in China, with the Ministry of Finance reporting a VAT revenue of 58.858 billion yuan in the first ten months of the year, representing a 4% year-on-year increase [3].

Core Points - The recent tax reform focuses on standardizing tax incentives, accelerating the adjustment of VAT policies across various industries [1] - The Ministry of Finance, the General Administration of Customs, and the State Taxation Administration have announced the cancellation or adjustment of several VAT incentives [1] Wind Power Industry - The VAT exemption policy for onshore wind power, which allowed a 50% immediate refund since July 1, 2015, will be abolished starting November 1, 2023 [2] - From November 1, 2025, to December 31, 2027, a similar 50% immediate refund policy will be retained for offshore wind power [2] - The decision reflects the maturity and competitiveness of onshore wind technology, while offshore wind still requires support due to higher costs and challenges [2] Nuclear Power Industry - The VAT policy that allowed a phased refund for nuclear power plants will be phased out for new projects approved after November 1, 2025 [3][4] - Existing nuclear power plants will continue to benefit from the previous VAT refund policies until their respective deadlines [4] - This change indicates that nuclear power is now expected to compete on equal tax terms with other energy sources [4] Financing Leasing Industry - The VAT refund policy for financing leasing businesses, which applied to tax burdens exceeding 3%, will be abolished on November 1, 2023 [5][6] Aircraft Maintenance and Other Industries - The VAT exemption for aircraft maintenance services, which allowed refunds for tax burdens exceeding 6%, will be canceled [7] - Other industries affected include diamond trading, new wall materials, and coalbed methane extraction, with various VAT incentives being removed [7][8] Overall Tax Policy Context - The cancellation of these tax incentives aligns with the broader goal of standardizing tax policies and increasing fiscal revenue amid economic challenges [8] - In the first three quarters of the year, the general public budget revenue was 163.876 billion yuan, a 0.5% increase year-on-year, while expenditures grew by 3.1% [9]

Core Points - The adjustment of tax incentives for certain industries, such as wind power generation, reflects the achievement of policy goals and the need for timely withdrawal of tax benefits [1][2] - The new policy maintains a 50% VAT refund for offshore wind power products from November 1, 2025, to December 31, 2027, indicating a targeted approach to support specific sectors [1][2] Group 1 - The adjustment aims to enhance the precision of tax policies by canceling VAT refunds for onshore wind power while retaining benefits for offshore wind power, addressing both economic development and cost factors [2] - The changes focus on specific industries, regions, and entities, promoting a fair tax environment and competition, which is essential for building a unified national market [2] - The adjustments are expected to improve the VAT system and support the upcoming implementation of the VAT law in 2026 [2]

Core Viewpoint - The acquisition of 55% stake in Shaanxi Ruisheng Biological Technology Co., Ltd. by Haili Biological has faced significant challenges, leading to a price adjustment from 9.35 billion to 5.36 billion yuan due to declining revenue and net profit caused by market competition and tightened tax policies [1][2][3] Group 1: Acquisition Details - Haili Biological announced a supplementary agreement to adjust the acquisition price of Ruisheng Biological's 55% stake from 9.35 billion yuan to 5.36 billion yuan, requiring the seller, Meilun Company, to return a price difference of 3.99 billion yuan [1][2] - The overall valuation of Ruisheng Biological was adjusted from 17 billion yuan to 9.74 billion yuan based on an asset assessment report as of June 30 [2] - The profit commitments for 2025 and 2026 were revised to 50 million yuan and 58 million yuan, respectively [1] Group 2: Performance Challenges - Ruisheng Biological's revenue and net profit have declined due to two main factors: increased competition in the market and the tightening of previously applicable tax incentives, which has led to a shift to a general taxation method with a 13% VAT rate [2][3] - The average price of Ruisheng Biological's oral product line dropped by 40% in Q2, despite a slight increase in market share of 6% to 7% [2] - The company has faced challenges in maintaining profitability due to significant price declines that cannot be offset by market share gains [2] Group 3: Strategic Shift - Haili Biological's acquisition of Ruisheng Biological is seen as a strategic move to enter the human health sector, transitioning from the animal health industry [1][3] - Ruisheng Biological specializes in regenerative medicine products, including oral bone repair materials and absorbable biological membranes [3][4] - The company has had recent success with the acceptance of registration applications for new medical devices aimed at jawbone defect repair [4]